Join us for #PanCANPurpleStride 2027 on Saturday, April 24! Bring your family and friends, join the PanCAN community and take steps to change the future of pancreatic cancer. Together, we can turn science into survival.  Visit 🔗 purplestride.org to register now! By registering early, you build momentum and create a bigger impact for people affected by pancreatic cancer. Every dollar you raise accelerates progress toward a future where every patient has access to the care, support and treatments that give them the best chance to survive. 👟💜

Pancreatic cancer is one of the most challenging cancers, but there is hope — and progress. Since 1999, PanCAN has been leading the fight against pancreatic cancer through research, patient support, advocacy and community action. We’re working to accelerate pancreatic cancer research, advance early detection, connect patients to the best care and improve survival. But our work isn’t finished. We won’t stop until pancreatic cancer is caught early, every patient has access to the treatment they deserve, and survival is the expectation — not the exception. It’s going to take all of us. Together, we can change the story of pancreatic cancer. 💜 Visit 🔗 pancan.org to learn more.

Join us for our second Right Track Live event, hosted by PanCAN Chief Scientific & Medical Officer Anna Berkenblit, MD, MMSc. We will bring together leading pancreatic neuroendocrine tumor (PNET) experts to share the latest information, answer common questions and provide practical insights into diagnosis, treatment and ongoing research. ⏺️ Save your seat at 🔗 pcan.at/RightTrackLive.

Your #PanCANPurpleStride team starts with you! Take the first step today and register as a Team Captain for PanCAN PurpleStride 2027, happening Saturday, April 24. And right now, when you register as a Team Captain and raise $50 toward your fundraising goal, we’ll send you an official Team Captain hat. This offer ends at 11:50 p.m. PT on Friday, October 9, so register and raise your $50 today! 🧢 Visit 🔗 purplestride.org to register. Let's take steps together to end pancreatic cancer. 💜

PanCAN President and CEO Julie Fleshman shares: "Last week was PanCAN’s annual Scientific Summit in San Diego ahead of #AACRpanc26, and I left feeling inspired by how far this field has come and energized by what lies ahead. The Summit brought together leading researchers, clinicians, industry partners, survivors and donors at a remarkable moment for pancreatic cancer. Following the approval of RASONQUE (daraxonrasib), there was a real sense of possibility in the room — from advances in RAS-targeted treatments to new approaches to earlier detection and the potential of health data. What made the experience especially meaningful to me was seeing PanCAN’s impact throughout the Summit. Researchers whose work we have funded shared their latest progress, our Research Recovery Grantees demonstrated the importance of sustaining critical science and nine emerging scientists joined us through PanCAN travel scholarships. These investments are helping build a thriving field — a core part of PanCAN’s mission and our role as a leader in accelerating progress. I’m proud of what we are helping make possible and deeply grateful to everyone who is contributing to this work. Together, we are truly turning science into survival." Stay tuned for key takeaways from the 2026 PanCAN Scientific Summit, shared by PanCAN Chief Scientific and Medical Officer Dr. Anna Berkenblit, coming in October. 🔬

At a time of extraordinary progress in pancreatic cancer research and treatment, we’re grateful for the support of our PanCAN Scientific & Medical Affairs Industry Champions, including our newest Champions: @ClearNoteHealth, @Immunovia, Tango Therapeutics and returning Champions @AstellasUS and Ipsen. Together, we’re turning science into survival. 💜

On this episode of PancChat, host @AlisynCamerota is joined by Dr. Eileen O’Reilly of @MSKCancerCenter to discuss what the recent approval of RASONQUE™ (daraxonrasib) means for people with pancreatic cancer. 💊 Dr. O’Reilly breaks down RAS signaling, common RAS mutations including G12D, G12V and G12R, how RAS-targeting drugs work, what RAS mutation testing involves and what “RAS wild type” means. Visit 🔗 pcan.at/PancChat to listen. The PancChat podcast is a collaboration between @LetsWinPC and PanCAN, and this episode is sponsored by @RevMedicines.

One of the most common conditions associated with pancreatic cancer may also be one of the least understood: Cancer cachexia. Sometimes known as wasting syndrome, cancer cachexia is the loss of 5% or more of body weight in six months. It is caused by many different factors that scientists are still trying to understand. It differs from weight loss because it is unintentional and happens even if the patient is still eating enough food to maintain their weight. Cancer cachexia is also different from weight loss because it affects muscles too. Instead of just losing weight from excess fat, cancer cachexia can cause significant muscle-wasting that can make patients feel weak and unable to withstand often intense cancer treatments. This muscle wasting can also include weakening of muscles of the heart and lungs, which makes early intervention important. This Cancer Cachexia Awareness Day, visit 🔗 pcan.at/po6j38 to learn more about this condition that affects more than 90% of people living with pancreatic cancer.

From meal planning and recipe ideas to facts about enzymes and tips from dietitians, PanCAN has you covered when it comes to information on nutrition. It's a subject as varied as the people facing pancreatic cancer, and we want to encourage you to eat foods that keep you strong, connected and full of joy. 💜 Visit 🔗 pancan.org/diet-and-nutritio… to learn more about how PanCAN can help.

Today, we remember Days of our Lives actor Drake Hogestyn, who passed away from pancreatic cancer in 2024 — just one day before his 71st birthday. His legacy lives on through his family and @DaysPeacock castmates, who come together at #PanCANPurpleStride, our biggest community event of the year, in his memory. In 2025, cast members formed Team Hogey’s Home Runners to honor their friend and co-star, returning again in 2026 to take steps to end pancreatic cancer. 💜 In 2026, an estimated 67,530 people in the U.S. will be diagnosed with pancreatic cancer, and approximately 52,740 will die from the disease. Learn more about pancreatic cancer and how we’re turning science into survival at 🔗 pancan.org. 📷: AoL

Join PanCAN Chief Scientific and Medical Officer Anna Berkenblit, MD, MMSc, for a Right Track Live virtual event focused on helping patients, caregivers and loved ones better understand pancreatic neuroendocrine tumors (also known as PNETs) and what recent advances mean for those affected by the disease. We will bring together leading PNET experts to share the latest information, answer common questions and provide practical insights into diagnosis, treatment and ongoing research. You’ll learn more about: 💜 How PNETs differ from the most common type of pancreatic cancer, including how they develop and why care often requires a specialized treatment approach. ⚠️ Common signs and symptoms that are unique to PNETs, including symptoms related to hormone changes that may be overlooked. 💊 Current treatment approaches and what patients should know about available targeted therapies and clinical trials. 🔬 Advances in PNET research and what it means for patients, including how to prepare for informed conversations with healthcare providers about treatment options and goals of care. Save your seat at 🔗 pcan.at/RightTrackLive.